

ARTICLE



Expansion of the neurodevelopmental phenotype of individuals with *EEF1A2* variants and genotype-phenotype study

Alix Paulet¹✉, Cavan Bennett-Ness², Faustine Ageorges¹, Detlef Trost³, Andrew Green⁴, David Goudie⁵, Rosalyn Jewell⁶, Minna Kraatari-Tiri^{7,8}, Juliette PIARD⁹, Christine Coubes¹⁰, Wayne Lam¹¹, Sally Ann Lynch¹², Samuel Groeschel¹³, Francis Ramond¹⁴, Joël Fluss¹⁵, Christina Fagerberg¹⁶, Charlotte Brasch Andersen¹⁷, Konstantinos Varvagiannis¹⁸, Tjitske Kleefstra^{19,20,21,22}, Bénédicte Gérard²³, Mélanie Fradin²⁴, Antonio Vitobello²⁵, Romano Tenconi²⁶, Anne-Sophie Denommé-Pichon^{27,28}, Aline Vincent-Devulder²⁹, Tobias Haack³⁰, Joseph A Marsh³¹, Lone Walentin Laulund³², Mona Grimm³⁰, Angelika Riess³⁰, Elke de Boer^{19,20,21}, Sergio Padilla-Lopez³³, Somayeh Bakhtiari³³, Adam Ostendorf^{34,35}, Christiane Zweier^{36,37}, Thomas Smol³⁸, Marjolaine Willems^{39,40}, Laurence Faivre^{41,42}, Marcello Scala^{43,44}, Pasquale Striano^{43,44}, Irene Bagnasco⁴⁵, Daniel Koboldt^{34,34}, Maria Iascone⁴⁶, Manon Suerink⁴⁷, Michael C Kruer³³, Jonathan Levy¹, Alain Verloes¹, Catherine M Abbott¹ and Lyse Ruud¹

© The Author(s), under exclusive licence to European Society of Human Genetics 2024, corrected publication 2024

Translation elongation factor eEF1A2 constitutes the alpha subunit of the elongation factor-1 complex, responsible for the enzymatic binding of aminoacyl-tRNA to the ribosome. Since 2012, 21 pathogenic missense variants affecting *EEF1A2* have been described in 42 individuals with a severe neurodevelopmental phenotype including epileptic encephalopathy and moderate to profound intellectual disability (ID), with neurological regression in some patients. Through international collaborative call, we collected 26 patients with *EEF1A2* variants and compared them to the literature. Our cohort shows a significantly milder phenotype. 83% of the patients are walking (vs. 29% in the literature), and 84% of the patients have language skills (vs. 15%). Three of our patients do not have ID. Epilepsy is present in 63% (vs. 93%). Neurological examination shows a less severe phenotype with significantly less hypotonia (58% vs. 96%), and pyramidal signs (24% vs. 68%). Cognitive regression was noted in 4% (vs. 56% in the literature). Among individuals over 10 years, 56% disclosed neurocognitive regression, with a mean age of onset at 2 years. We describe 8 novel missense variants of *EEF1A2*. Modeling of the different amino-acid sites shows that the variants associated with a severe phenotype, and the majority of those associated with a moderate phenotype, cluster within the switch II region of the protein and thus may affect GTP exchange. In contrast, variants associated with milder phenotypes may impact secondary functions such as actin binding. We report the largest cohort of individuals with *EEF1A2* variants thus far, allowing us to expand the phenotype spectrum and reveal genotype-phenotype correlations.

European Journal of Human Genetics (2024) 32:1144–1149; <https://doi.org/10.1038/s41431-024-01560-8>

¹Département de Génétique, Hôpital Robert-Debré, Paris, France. ²Centre for Genomic and Experimental Medicine and Simons Initiative for the Developing Brain, Institute of Genetics and Cancer, Edinburgh, Scotland, UK. ³Laboratoire Cerba, Saint-Ouen l'Aumône, France. ⁴UCD School of Medicine and Medical Science Consultant in Clinical Genetics, Dublin, Ireland. ⁵Regional Genetics Service, NHS Tayside, Dundee, Scotland, UK. ⁶Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, England, UK. ⁷Department of Clinical Genetics, Research unit of Clinical Medicine, Medical Research Center Oulu, Oulu, Finland. ⁸Oulu University Hospital and University of Oulu, Oulu, Finland. ⁹Centre de Génétique Humaine, CHU Besançon, Besançon, France. ¹⁰Service de Génétique Médicale, CHU de Montpellier, Montpellier, France. ¹¹South-East of Scotland Clinical Genetics Service, General Hospital, Edinburgh, Scotland, UK. ¹²Clinical Genetics, Children's Health Ireland, Dublin, Ireland. ¹³Department of Neuropediatrics, University Children's Hospital, Tuebingen, Germany. ¹⁴Service de Génétique, CHU Saint-Etienne - Hôpital Nord, Saint-Etienne, France. ¹⁵University Hospitals of Geneva, Geneva, Switzerland. ¹⁶Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. ¹⁷Human Genetik, Syddansk Universitet, Odense, Denmark. ¹⁸Service de Médecine Génétique, Hôpitaux universitaires de Genève, Geneva, Switzerland. ¹⁹Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands. ²⁰Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. ²¹Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands. ²²Center of Excellence for Neuropsychiatry, Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands. ²³Molecular Biology, Nouvel Hôpital Civil, Strasbourg, France. ²⁴Service de Génétique Médicale, Hôpital Sud, CHU de Rennes, Rennes, France. ²⁵UMR-Inserm, Génétique des Anomalies du développement, Université de Bourgogne Franche-Comté, Dijon, France. ²⁶Servizio di Genetica Medica, Dipartimento di Pediatria, Padova, Italia. ²⁷Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France. ²⁸UMR1231 GAD, Inserm - Université Bourgogne-Franche Comté, Dijon, France. ²⁹Génétique Médicale, CHU de Caen, Caen, France. ³⁰Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. ³¹MRC Human Genetics Unit, Western General Hospital, University of Edinburgh, Edinburgh, Scotland, UK. ³²H C Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. ³³Pediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, AZ, USA. ³⁴Steve and Cindy Rasmussen Institute for Genomic Medicine Nationwide Children's Hospital, Columbus, Ohio, USA. ³⁵Department of Pediatrics, The Ohio State University College of Medicine, Columbus, USA. ³⁶Department of Human Genetics, Inselspital Bern, University of Bern, 3010 Bern, Switzerland. ³⁷Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany. ³⁸University of Lille, EA7364-RADEME, Medical Genetics Institute, CHU Lille, Lille, France. ³⁹Medical Genetic Department for Rare Diseases and Personalized Medicine, Reference Center AD SOOR, AnDDI-RARE, Groupe DI, Inserm U1298, INM, Montpellier University, Montpellier, France. ⁴⁰Centre Hospitalier Universitaire de Montpellier, Montpellier, France. ⁴¹UMR1231 GAD, Inserm, Université de Bourgogne-Franche Comté, Dijon, France. ⁴²Centre de Référence Maladies Rares « Anomalies du développement et syndromes malformatifs », Centre de Génétique, FHU-TRANSLAD et Institut GIMI, CHU dijón, Bourgogne, Dijon, France. ⁴³Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy. ⁴⁴Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy. ⁴⁵Division of Child Neuropsychiatry, Martini Hospital, Torino, Italy. ⁴⁶Laboratorio Di Genetica Medica, Bergamo, Italy. ⁴⁷Department of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands. ✉email: alix.paulet@hotmail.fr

Received: 16 June 2023 Revised: 10 January 2024 Accepted: 1 February 2024

Published online: 15 February 2024

INTRODUCTION

The eEF1 family of eukaryotic elongation factor genes, which comprises the two paralog eEF1A proteins eEF1A1 and eEF1A2 and the 3 subunits of the eEF1B complex (eEF1B α , eEF1B β , and eEF1B γ) encodes integral components of the translation elongation factor complexes whose function is delivery of aminoacyl tRNA to ribosome during the elongation step of protein synthesis [1]. The two eEF1A proteins, the second most abundant protein in the cell [2], share 92% identity. eEF1A binds aa-tRNAs in a GTP-dependent manner, relying on its cognate guanine exchange factor (GEF), eEF1B, to recycle the inactive eEF1A-GDP complex into the active GTP-bound form. *EEF1A1* gene is expressed almost ubiquitously. *EEF1A2* is expressed mainly in muscle (including cardiac muscle) and in neurons [3,4]. During development, eEF1A1 is down-regulated in muscle and neurons and is undetectable in mouse muscle by 3 weeks post-natal [5,6].

No pathogenic *EEF1A1* variants have been described, presumably because they would not be compatible with life [7]. In contrast, in 1972, a deletion of 15.8 kb that abolishes expression of eEF1A2 (MIM_01958) was discovered in mice that developed motor neuron degeneration, muscle atrophy, gait abnormalities and then died by four weeks [3,5]. A trio-based exome in 2012 revealed a *EEF1A2* variant in a patient with early onset epilepsy, severely delayed psychomotor development, and autistic behavior [8]. Subsequent individual reports and a series of 14 patients [9] allowed to further delineate the neurodevelopmental phenotype, combining moderate to severe Intellectual Disability (ID), epilepsy, Autism Spectrum Disorder (ASD), sleep disorders, neurodegeneration and movement disorders [9–13].

Since 2012, 21 *EEF1A2* variants have been reported [8–27]. All variants are missense. In one pedigree, a variant was inherited from a parent with less than 25% of mosaicism [9]. Other variants were de novo. To date, no genotype-phenotype correlation has been studied.

Through an international collaboration, we collected data on 26 unreported *EEF1A2* patients, the largest cohort to date, and investigated possible genotype-phenotype correlations.

MATERIAL AND METHODS

Individual ascertainment

Between December 2020 and December 2021, 26 individuals with variants in *EEF1A2* were identified through European Reference Network ERN-

ITHACA (<https://ern-ithaca.eu/>) using its collaborative call system. Patients were evaluated by a geneticist. Written informed consents for DNA and data analyses were obtained from individuals or their legal guardians.

Cognitive assessment

Out of the 26 patients included in our study, we assessed cognitive abilities for 13 individuals (Table 1): six underwent a Wechsler Intelligence Scales for Children according to age (Scales IV and V: 6 years to 16 years 11 months old, or Wechsler Preschool and Primary Scale of Intelligence III or IV: 4 years to 7 years 3 months old) and 7 patients were evaluated by clinicians (Supplementary Table S1).

Among 6 patients which performed Wechsler tests, only 4 of the 6 patients had a computable Total Intelligence Quotient (TIQ). For the remaining two, they had too heterogenous profiles to allow TIQ calculation. We therefore utilized the available indices data (VCI, FRI, VSI, WMI, PSI) to estimate their intellectual levels.

For the 7 patients evaluated by clinicians, cognitive assessments were provided but we did not have quantitative data (Supplementary Table S1).

Patients were divided into 4 categories such as “not ID” for TIQ ≥ 70 , “mild ID” for $50 \leq \text{IQ} < 70$, “moderate ID” for $35 \leq \text{IQ} < 50$, and “severe ID” for $\text{IQ} < 35$, according to their IQ scores especially TIQ. In total, we classified 13 patients according to their level of intellectual efficiency (Table 1).

We excluded 13 individuals of cognitive analysis because they were too young at the last follow-up appointment or they have been lost to follow-up.

To categorize individuals from the literature when Weschler’s Full-Scale Intelligence Quotient (FSIQ) was not available, we took into account the authors’ assigned category ID for each individual or we used the information on individual developmental milestones (walking age, capacity for language, verbal abilities...) to estimate the developmental delay as “mild”, “moderate” or “severe” phenotype (Supplementary Table S2). The individuals whose information was insufficient to be to be classified into these categories were not scored.

Genetic investigations

DNA was extracted from the peripheral blood leukocytes of the patients and parents (whenever possible) using standard procedures.

In 24/26 patients, genotyping was performed by exome sequencing (ES) (single or trio) using routine methods. Confirmation and segregation of variants in single ES were carried out by Sanger sequencing. Variant prioritization was conducted according to the transmission mode (de novo, autosomal recessive and X-linked), and the frequency of the variants in the gnomAD database. Those variants were classified according to American College of Medical Genetics (ACMG) (ACMG and Combined Annotation Dependent Depletion (CADD) score in Supplementary data, Supplementary Table S3). There were no other pathogenic variants in ClinVar and HGMD or loss-of-function variants which could explain the patient phenotypes. Two variants were identified on a NGS panel of 119 ID genes using standard NGS procedures.

Protein modeling

The structures of eEF1A2*GDP (4C0S), eEF1A γ *eEF1B α (pdb: 1UJF), aEF1A*GTP (pdb: 3AGJ), and EF-TU*EF-TS (pdb: 1EFU) were used for analysis using Pymol (The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC.) and CCP4MG [28]. Structure-based variant predictions made using Missense 3D [29] and dimer predictions using FoldX [30]. Briefly, eEF1A2 (pdb: 4C0S) was repaired, then the protein stability was estimated for each amino acid change in both monomeric and the dimeric eEF1A2.

Statistical analysis

We compared our patients to the previously reported ones. We used Student Test with bilateral hypothesis, have tolerated a risk of error of less than 5% (p -value < 0.05).

Literature review

PubMed was searched for peer-reviewed articles published in English using the following keywords: «*EEF1A2*», «epileptic encephalopathy gene», «*EEF1A*» «phenotype of *EEF1A2*» «*EEF1A2* with no intellectual disability» «epilepsy gene».

RESULTS

In our series, the mean age at last examination is 10.67 years vs. 9.6 years for literature patients (Supplementary Table S4). The mean

Table 1. Cognitive abilities of patients in our series compared to those previously reported.

Cognitive evaluation	Cohort (13 patients)	Literature (33 patients)	P-value	CI 95%
No ID	23% (3)	0%	0.082	[−0.03; 0.49]
Mild	31% (4)	3% (1)	0.063	[−0.02; 0.57]
Moderate	15% (2)	6% (2)	0.418	[−0.14; 0.33]
Severe ^a	31% (4)	76% (25)	0.008	[−0.77; −0.13]
Profound ^a	0	15% (5)	0.023	[−0.28; −0.02]

This table shows comparison in terms of cognitive abilities between our patients and the previously reported ones. The 4 categories classification strategy has been explained in the Material and Method section. The number of patients are in parentheses.

CI Confidence Interval.

^aMeans the comparison is statistically significant, p -value < 0.05 .




Fig. 1 Our series main features compared with the patients from the literature. The Fig. 1 shows the proportion of our patients (in black) in comparison to those from the literature (featured in gray) according to the main criteria studied. Walking abilities is represented by the motor category. Concerning the speech abilities, “verbal” means the patient can speak and be understandable, “words” means he can express himself in words but not in sentences, “sentences” stands for the ability of the patient to make proper sentences. On the right part of the diagram, the neurological features are shown with the presence of hypotonia, pyramidal syndrome, epilepsy and the presence of regression. *Stands for statistically significance $p < 0.05$. P-values are framed at the top.

Table 2. Cohort and literature comparison regarding epilepsy and brain MRI characteristics.

		Cohort	Literature	p-value	CI 95%
Epilepsy	Epilepsy refractory to therapy	25% 3/12	50% 15/30	0.13	[−0.58; 0.08]
	Epileptic encephalopathy	7% 1/15	24% 9/38	0.085	[−0.36; 0.02]
Brain MRI	Normal	50% 11/22	47% 15/32	0.8258	[−0.25; 0.31]
	Thin corpus callosum	14% 3/22	17% 5/30	0.767	[−0.23; 0.17]
	Delayed myelinization	9% 2/22	13% 4/30	0.636	[−0.22; 0.13]
	White and gray matter abnormalities	27% 6/22	9% 3/32	0.114	[−0.04; 0.40]
	Cerebellar and cortical atrophy ^a	9% 2/22	34% 11/32	0.0207*	[−0.46; −0.04]

This table shows comparison between our cohort and the previously reported cases regarding epilepsy and brain MRI features. P-value and CI 95% are mentioned.

CI Confidence Interval.

^aWhen significant.

Occipito-Frontal Circumference (OFC) is -0.67 SD (vs. -1.33 SD) (Supplementary Table S4). Most patients can walk on independently. The mean age for acquiring walking is 30 months. For the 4 individuals in the literature this mean is 39 months, p -value = 0.41 (Supplementary Table S4).

Among 18 individuals aged more than 2 years, 83% are verbal (Fig. 1) with a mean age of first words at 29 months (Supplementary Table S4) (data not available for published cases). The average age at onset of epilepsy is 3.5 years (Supplementary Table S4) (data not available for previously reported patients).

Neuropsychologist assessments were performed in six patients (Table 1). For the 4 patients for whom a TIQ could be calculated, the FSIQ ranged from 40 to 77 (mean = 60.2; median = 58.5) (Supplementary Table S1).

Patient 1 has a FSIQ in the low normal range (77) and the two others (patients 6 and 19) have several indexes >70 despite their heterogeneous profile do not allow to compute FSIQ. Patient 19 has a FSIQ of 69, but with low normal verbal comprehension index (76) and fluid reasoning (71) (Supplementary Table S1).

In our cohort of 13 for whom we have developmental information, 4 patients have a phenotype described as severe (31%) compared to those from the literature (76%) p -value = 0.008 (-0.77 ; -0.13) (Table 1). Among published patients, 5/33 (15%) have profound ID (Table 2), whereas there is no patient classified as having profound ID in our cohort. There is no difference observed concerning mild and moderate ID (Table 1).

The individuals of this series are more ambulant than previous reported ones: 82% (18/22) vs. 29% (10/34), p -value = 0.00004 (0.29; 0.76). They are more likely to have acquired language (83% vs. 14% p -value = $10E-7$ (0.47; 0.91)) (Fig. 1).

In our cohort, less patients have hypotonia and pyramidal syndrome (Fig. 1). There is no difference in the incidence of ataxia and ASD. A majority of our patients have sleep disorders (11/24), with limited effectiveness of melatonin treatment (Supplementary Table S1). Half of our patients (53% 9/17) have ADHD (Supplementary Table S1). More than a half of our patients (14/25) have gross motor issues with mainly unstable walk, and 77% (17/22) have fine motor issues particularly concerning coordination (Supplementary Table S1).

We also compared our patients to the previously described ones regarding several items. The percentage of patients with epilepsy refractory to therapy, the percentage with epileptic encephalopathy were compared, so as our series brain MRI features. The results are presented in Table 2.

We report 8 new *EEF1A2* variants (T24M, R96H, D97N, T104R, G356S, D362N, P420L, V437F) with detailed phenotyping. Phenotypes observed varies from mild to severe (Fig. 2a). The patients with variants T24M and R96C have no ID but are symptomatic: have epilepsy (R96C) or speech delay with first sentences at age 6 (T24M). For patients with P420L and V437F, we could not document ID because of the lack of psychometric evaluation (Supplementary Table S1).




Fig. 2 Distribution of pathogenic *EEF1A2* variants. **a** Distribution of variants from our cohort (up) and the previously reported ones (down). Novel variants are underlined. Variants are classified by their associated phenotype in terms of ID, classification is as described as above with associated symbols (circle for not deficient, triangle for mild ID, square for moderate ID and star for severe). Blank when the variant is not clearly classified (for example when associated with 2 ID categories). **b** Variants mapped onto the crystal structure of GDP-bound eEF1A2 (PDB:4C0S). New variants are shown in black, with labels in bold, previously described mutations are in white. T24M and V437F are buried. The binding site of eEF1B is highlighted in white, and the GTP binding site in dark gray.

Molecular modeling

We explored the impact of the variants through 3D-modeling of eEF1A2, comparing the GDP-bound form of eEF1A2 (pdb:4C0S) with eEF1A γ *eEF1B α (pdb:1IJF), aEF1A*GTP (pdb:3AGJ), and EF-TU*EF-TS (pdb:1EFU). All variants have CADD scores above 20 (Supplementary Table S3).

Mapping of the variants onto the structure of eEF1A2 (Fig. 2b) showed that several of the variants cluster around the switch II region, a flexible motif key for GTP hydrolysis and GEF-mediated GDP dissociation. R96C, R96H, and D97N are found in a loop in the Switch II region, whilst T104R, R381W, and V437F are situated nearby. These variations are anticipated to contribute towards switch II destabilization and interfere with GTP recycling, whilst another variant, T24M, is located at the GTP-binding pocket, and is predicted to directly disrupt nucleotide binding (Supplementary modeling in Supplemental data).

Further from the GDP-binding or switch regions, several variations (E297K, G356S, D362N, and P420L) are located near the actin binding region (Fig. 2b) and are anticipated to disrupt actin-related functions

(Supplementary modeling). Three of these variants, E297K, D362N and P420L are located near the tRNA-binding site, and may affect eEF1A2 interactions with aminoacyl-tRNA. Given the overlap between the binding sites for actin and aa-tRNAs and the eEF1B-binding region, some of these variants may also impact eEF1B binding. Additionally, the presence of variants T104R and D362N on the dimer interface, and the change in amino acid charge, suggest they may influence eEF1A2 dimer formation (Supplementary modeling).

DISCUSSION

Widening *EEF1A2*-related spectrum

Our results show that patients with *EEF1A2* variants can have efficient cognitive abilities. Indeed, in our cohort, 3 individuals do not have an intellectual disability (IQ > 70), while in the literature, no patients are reported with preserved intellectual efficiency. In addition, within our cohort, the severity of ID is lower, with a majority of patients with mild to moderate ID.

In terms of development, the majority of our individuals have access to language and walking, contrary to what has already been described.

Taken together, the phenotypic spectrum associated with *EEF1A2* variants is wider than previously suggested. All previously reported patients had intellectual disabilities and the majority (93%) were epileptic and nonverbal. We have shown that individuals with *EEF1A2* variants may have milder phenotypes and that nearly half of them do not have epilepsy at time of report. Epilepsy can be late-onset, as illustrated by patient 7 (ref. ²⁰) with the D252H variant who did not develop epilepsy until age of 8 and the average age in the cohort is 10.7 years.

Young individuals are difficult to assess using the WPPSI-IV or WISC scales. There are 13 individuals who have received cognitive evaluation but only 4/13 have a valid TIQ because profiles are too heterogeneous. For this study, we chose to take the heterogeneous profiles into account even if partial Weschler' scales remain an objective way to evaluate individuals' cognitive capacities.

To date, the only reported patient of autosomal dominant inherited *EEF1A2* variant was from a mother with <25% of mosaicism [9] but there was no clinical information available. We newly report 2 patients (patient 6 (whose father is patient 7) and patient 20) with inherited variants from an asymptomatic parent (in terms of neurodevelopmental disorder) which suggests an incomplete penetrance of these variants (G356S and R96C). G356S is not reported in the database and the position of the residue is highly conserved. For G356S, the asymptomatic parent has a history of irregular heartbeat, and he has at least 3 relatives who had seizures (the relatives have not been tested for the variant yet). One individual (patient 6) has the variant R96C inherited from his affected father (patient 7), this variant had been shown to be associated with Genetic Generalized epilepsies (GGE) [27]. No mosaicism detected in unaffected parents.

These two examples of inherited *EEF1A2* variants strongly suggest incomplete penetrance. Although only 3 patients (including our 2) are reported so far, incomplete penetrance should be considered in *EEF1A2* variants. More individuals are needed to confirm this hypothesis and we recommend to test proband's parents even if there are apparently not affected. This incomplete penetrance is relevant to genetic counseling.

We can notice a fairly variability of expression in patients with the same variation. For example, in our series, patients 15, 16 and 17 have the same E124K variant already reported by Kaur et al. [15]. Whereas patients 15, 16 and Kaur et al. patient acquired independent walk before 2 years with good language abilities and epilepsy, our patient 17 acquired walk at 4 years and had no epilepsy.

We also report 2 patients (11 and 5) with de novo *EEF1A2* variant mosaicism which did not cause milder phenotypes. Patient 11 presents epileptic encephalopathy and has TIQ of 52 at 3 years. Patient 5 can speak in sentences. Nevertheless, they have some similarities: they both have white and gray matter abnormalities on brain MRI and focal epilepsy, controlled with antiepileptic treatment. Concerning patient 5, the variation D91N has been reported three times in the literature in patients with severe to profound ID and early onset epilepsy [9, 15, 18], whereas our patient is obviously less severe affected than the three others. This mosaicism (estimated to 23%) could have caused bias in comparison because this milder phenotype is possibly only a result of mosaicism. So, mosaicism state should be taken into account while considering an *EEF1A2* variant, although the impossibility to estimate percentage of mosaicism in brain makes the phenotype difficult to be predicted.

Ten patients [9, 10, 12, 22, 23] have been reported to have regression in childhood. In our cohort, only patient 22 (R381W) has shown regressive traits which began in her third decade (but she is also the only individual to have reached this age). She has started to show less interest in activities she used to like such as writing, swimming and she lost some abilities. This individual suggests that regression may appear later than we thought while

reviewing the literature patients (where most of patients showed regression in infancy [9]). It's clear that patients must be followed up and supported to prevent complications during time.

Molecular insights

Plotting the patients' variants and those previously described on the surface of the eEF1A2 protein (Fig. 2b) suggests that variants, resulting in severe ID are generally clustered around the switch I and switch II regions, or nucleotide/GEF binding sites for GTP and GTP exchange factor eEF1B. The growing cluster of variants around the switch II region or GDP-binding site (Fig. 2b) suggests that disruption of GDP-binding and GEF-induced GDP dissociation may be a key mechanism for the NDD-causing *EEF1A2* missense variants, adding to the evidence from Carvill et al. [9]. Four of the 19 variants classified as severe directly coincide with defined eEF1B binding sites (Fig. 2b).

Many of the milder variants map further away but could affect tRNA or actin binding (Fig. 2b). There is evidence that E295K, the equivalent E297K mutation in yeast, affects translational fidelity. Variants affecting translational fidelity might be less likely to affect neurodevelopment, but would be anticipated to lead to neurodegeneration, which is observed in a subset of individuals with *EEF1A2* variants. There is also the possibility that these variants are not pathogenic and the cause of the individual phenotype was misunderstood.

CONCLUSION

We have described a cohort of individuals with a less severe phenotype, though they share characteristics such as developmental delay (especially speech delay), mild to severe intellectual disability, ASD, ADHD, early onset epilepsy, hypotonia, ataxia and sleep disorder which are concordant with the features related to variants in this gene in the literature. We suggest the existence of incomplete penetrance of certain variants which was not described so far with *EEF1A2*. Our series illustrate how the evolution of diagnostic strategies may lead to redefine the phenotypic spectrum of known genes that have been initially reported with a homogeneous and usually "severe" phenotype. There was probably an ascertainment bias in older patients that were more likely to be reported because they were severe, and were perhaps selected on this basis. The widespread adoption of the whole genome and whole exome sequencing, which results in an agnostic pan-genomic evaluation lead to the diagnosis of patients that would not be sent to targeted panel diagnosis. The first genotype-phenotype correlations are emerging, but new patients will be necessary to confirm these correlations.

To conclude, we expanded the phenotype spectrum and described new *EEF1A2* variants.

DATA AVAILABILITY

All anonymized data and related documentation from this study are available on reasonable request. Declaration to public database: All variants are reported and annotated in ClinVar website (accession number SCV004171535- SCV004171551): <https://www.ncbi.nlm.nih.gov/clinvar/>.

REFERENCES

- Kahns S, Lund A, Kristensen P, Knudsen CR, Clark BF, Cavallius J, et al. The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein. *Nucleic Acids Res.* 1998;26:1884–90. <https://doi.org/10.1093/nar/26.8.1884>.
- Abbott CM, Newbery HJ, Squires CE, Brownstein D, Griffiths LA, Soares DC. eEF1A2 and neuronal degeneration. *Biochem Soc Trans.* 2009;37:1293–7. <https://doi.org/10.1042/BST0371293>.
- Newbery HJ, Loh DH, O'Donoghue JE, Tomlinson VAL, Chau Y-Y, Boyd JA, et al. Translation elongation factor eEF1A2 is essential for post-weaning survival in mice. *J Biol Chem.* 2007;282:28951–9. <https://doi.org/10.1074/jbc.M703962200>.

4. Knudsen SM, Frydenberg J, Clark BF, Leffers H. Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha. *Eur J Biochem.* 1993;215:549–54. <https://doi.org/10.1111/j.1432-1033.1993.tb18064.x>.
5. Chambers DM, Peters J, Abbott CM. The lethal mutation of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation factor 1alpha, encoded by the Eef1a2 gene. *Proc Natl Acad Sci USA.* 1998;95:4463–8. <https://doi.org/10.1073/pnas.95.8.4463>.
6. Khalyfa A, Carlson BM, Dedkov EI, Wang E. Changes in protein levels of elongation factors, eEF1A-1 and eEF1A-2/S1, in long-term denervated rat muscle. *Restor Neurol Neurosci.* 2003;21:47–53.
7. McLachlan F, Sires AM, Abbott CM. The role of translation elongation factor eEF1 subunits in neurodevelopmental disorders. *Hum Mutat.* 2019;40:131–41. <https://doi.org/10.1002/humu.23677>.
8. De Ligt J, Willemsen MH, van Bon BWM, Kleefstra T, Yntema HG, Kroes T, et al. Diagnostic exome sequencing in persons with severe intellectual disability. *N. Engl J Med.* 2012;367:1921–9. <https://doi.org/10.1056/NEJMoa1206524>.
9. Carvill GL, Helbig KL, Myers CT, Scala M, Huether R, Lewis S, et al. Damaging de novo missense variants in EEF1A2 lead to a developmental and degenerative epileptic-dyskinetic encephalopathy. *Hum Mutat.* 2020;41:1263–79. <https://doi.org/10.1002/humu.24015>.
10. Veeramah KR, Johnstone L, Karafet TM, Wolf D, Sprissler R, Salogiannis J, et al. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. *Epilepsia.* 2013;54:1270–81. <https://doi.org/10.1111/epi.12201>.
11. Long K, Wang H, Song Z, Yin X, Wang Y. EEF1A2 mutations in epileptic encephalopathy/intellectual disability: Understanding the potential mechanism of phenotypic variation. *Epilepsy Behav.* 2020;105:106955. <https://doi.org/10.1016/j.yebeh.2020.106955>.
12. Inui T, Kobayashi S, Ashikari Y, Sato R, Endo W, Uematsu M, et al. Two cases of early-onset myoclonic seizures with continuous parietal delta activity caused by EEF1A2 mutations. *Brain Dev.* 2016;38:520–4. <https://doi.org/10.1016/j.braindev.2015.11.003>.
13. Cao S, Smith LL, Padilla-Lopez SR, Guida BS, Blume E, Shi J, et al. Homozygous EEF1A2 mutation causes dilated cardiomyopathy, failure to thrive, global developmental delay, epilepsy and early death. *Hum Mol Genet.* 2017;26:3545–52. <https://doi.org/10.1093/hmg/ddx239>.
14. Kaneko M, Rosser T, Raca G. Dilated cardiomyopathy in a patient with autosomal dominant EEF1A2-related neurodevelopmental disorder. *Eur J Med Genet.* 2021;64:104121. <https://doi.org/10.1016/j.ejmg.2020.104121>.
15. Kaur S, Van Bergen NJ, Gold WA, Eggers S, Lunke S, White SM, et al. Whole exome sequencing reveals a de novo missense variant in EEF1A2 in a Rett syndrome-like patient. *Clin Case Rep.* 2019;7:2476–82. <https://doi.org/10.1002/ccr3.2511>.
16. Zacher P, Mayer T, Brandhoff F, Bartolomeaus T, Le Duc D, Finzel M, et al. The genetic landscape of intellectual disability and epilepsy in adults and the elderly: a systematic genetic work-up of 150 individuals. *Genet Med J Am Coll Med Genet.* 2021;23:1492–7. <https://doi.org/10.1038/s41436-021-01153-6>.
17. Lopes F, Barbosa M, Ameur A, Soares G, de Sà J, Dias AI, et al. Identification of novel genetic causes of Rett syndrome-like phenotypes. *J Med Genet.* 2016;53:190–9. <https://doi.org/10.1136/jmedgenet-2015-103568>.
18. Lam WWK, Millichap JJ, Soares DC, Chin R, McLellan A, FitzPatrick DR, et al. Novel de novo EEF1A2 missense mutations causing epilepsy and intellectual disability. *Mol Genet Genom Med.* 2016;4:465–74. <https://doi.org/10.1002/mggg.3.219>.
19. de Kovel CGF, Brilstra EH, van Kempen MJA, Van't Slot R, Nijman IJ, Afawi Z, et al. Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients. *Mol Genet Genom Med.* 2016;4:568–80. <https://doi.org/10.1002/mggg.3.235>.
20. Nakajima J, Okamoto N, Tohyama J, Kato M, Arai H, Funahashi O, et al. De novo EEF1A2 mutations in patients with characteristic facial features, intellectual disability, autistic behaviors and epilepsy. *Clin Genet.* 2015;87:356–61. <https://doi.org/10.1111/cge.12394>.
21. Ostrander BEP, Butterfield RJ, Pedersen BS, Farrell AJ, Laver RM, Ward A, et al. Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy. *NPJ Genom Med.* 2018;3:22. <https://doi.org/10.1038/s41525-018-0061-8>.
22. De Rinaldis M, Giorda R, Trabacca A. Mild epileptic phenotype associates with de novo eef1a2 mutation: Case report and review. *Brain Dev.* 2020;42:77–82. <https://doi.org/10.1016/j.braindev.2019.08.001>.
23. Lance EI, Kronenburger M, Cohen JS, Furmanski O, Singer HS, Fatemi A. Successful treatment of choreo-athetotic movements in a patient with an EEF1A2 gene variant. *SAGE Open Med Case Rep.* 2018;6:2050313X18807622. <https://doi.org/10.1177/2050313X18807622>.
24. O'Roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. *Nat Commun.* 2014;5:5595. <https://doi.org/10.1038/ncomms5595>.
25. Helbig KL, Farwell Hagman KD, Shinde DN, Mroske C, Powis Z, Li S, et al. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. *Genet Med.* 2016;18:898–905. <https://doi.org/10.1038/gim.2015.186>.
26. Vogt LM, Lorenzo M, Prendergast B, Jobling D, Gill R. P. J. EEF1A2 pathogenic variant presenting in an infant with failure to thrive and frequent apneas requiring respiratory support. *Am J Med Genet A.* 2022;188:3106–9. <https://doi.org/10.1002/ajmg.a.62932>.
27. Epi25 Collaborative. Electronic address: jm4279@cumc.columbia.edu; Epi25 Collaborative. Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals. *Am J Hum Genet.* 2021;108:965–82. <https://doi.org/10.1016/j.ajhg.2021.04.009>.
28. McNicholas S, Potterton E, Wilson KS, Noble MEM. Presenting your structures: the CCP4mg molecular-graphics software. *Acta Cryst* 2011;D67:386–94.
29. Ittisoponpisan S, Islam SA, Khanna T, Alhuzimi E, David A, Sternberg MJE. Can Predicted Protein 3D Structures Provide Reliable Insights into whether Missense Variants Are Disease Associated? *J Mol Biol* 2019;431:2197–212. <https://doi.org/10.1016/j.jmb.2019.04.009>.
30. Van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, Rousseau F. A graphical interface for the FoldX forcefield. *Bioinformatics.* 2011;27:1711–2.

ACKNOWLEDGEMENTS

We want to acknowledge AnDDI-Rares and the families for their participation. In addition, the collaboration in this study were facilitated by ERN ITHACA, one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States, cofounded by European Commission. [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516].

AUTHOR CONTRIBUTIONS

Conceptualization: AP, LR, CA, AV. **Formal Analysis:** AP. **Investigation:** AP, FA, LR, MCK, SB, JL, DT, SB, MCK, AV, RT, CBA, MG, BG, SP, AO, CZ, TS, MW, LF, MS, PS, IB, DK, MI, MS. **Supervision:** LR, AV, CA. **Visualization:** AP, CA, CBN. **Writing - Original Draft:** AP, LR, CA, CBN. **Writing - Review & Editing:** AP, LR, CA, CBN, AV, FM, CC, RF, JP, SJ, CF, LW, JF, AV, ASDP, TH, JM, SAL, WL, RJ, MK, DG, AG, EDB, JL, DT, SB, MCK, AV, RT, CBA, MG, BG, SP, DK.

FUNDING

The aims of this study contribute to the Solve-RD project, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 779257.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICAL APPROVAL

Ethical approval was not required because it was a retrospective observational study and patients have already signed consent for genetics analyses for diagnosis. Every patient has been anonymized by the clinician before collecting data (a number has been assigned to each patient).

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41431-024-01560-8>.

Correspondence and requests for materials should be addressed to Alix Paulet.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.